Retatruetide 10mg

Retatrutide is an experimental, next-generation weight-loss and type 2 diabetes medication developed by Eli Lilly and Company. Dubbed a "triple agonist" or "triple G" molecule, it is the first metabolic drug in clinical development to target three different hunger and metabolic hormone receptors simultaneously: GLP-1, GIP, and glucagon. In late-stage Phase 3 clinical trials, retatrutide has demonstrated unprecedented weight loss efficacy, with participants losing an average of 28.3% of their total body weight over 80 weeks on the highest dose.

How Retatrutide WorksWhile existing medications like Ozempic (semaglutide) target only one hormone receptor (GLP-1), and Zepbound (tirzepatide) targets two (GLP-1 and GIP), retatrutide targets three. It works by mimicking:GLP-1 (Glucagon-Like Peptide-1): Suppresses appetite, increases feelings of fullness, and slows stomach emptying.GIP (Glucose-Dependent Insulinotropic Polypeptide): Enhances insulin production in response to blood sugar and optimizes how the body breaks down fat.Glucagon (GCG): Directly signals the liver to increase energy expenditure, meaning it actively forces the body to burn more calories and fat throughout the day.Clinical Efficacy and Trial DataData presented from the Eli Lilly clinical trials highlight unmatched weight loss and metabolic outcomes:Weight Loss: Phase 3 data from the TRIUMPH-1 trial showed a historic 28.3% average body weight reduction at the highest 12 mg weekly dose over 80 weeks. This magnitude of weight loss matches or exceeds the outcomes typically expected from bariatric surgery.Blood Sugar & Diabetes: In patients with type 2 diabetes, retatrutide lowered HbA1c levels by an average of up to 2.0%, pushing many participants into diabetes remission.